Armaceutica, Inc.

As a pharmaceutical start-up we're developing a cancer drug. The lack of serious side effects gives our drug a competitive advantage over other cancer drugs.

  • Stage Product In Development
  • Industry Biotechnology
  • Location El Paso, TX, USA
  • Currency USD
  • Founded January 2018
  • Employees 9
  • Incorporation Type C-corp
  • Website http://armaceutica.com

Company Summary

Repurposing malaria drug to treat cancer.

The disruptive advantage of our drug: It is essentially free from the serious side effects associated with chemotherapies.

Uni of TX published data drug kills cancer cells.

Patent in Australia, EU, Japan, US, Mexico & others.

Goal is to license or sell our IP to a med/large pharma. That's our exit in 1 to 2 years. For cancer drugs such deals typically fetch between $200 million and $2 billion.

Team

  • Ernest Armstrong
    Founder and CEO

    He directed clinical research since the 1990s including late-stage programs, budgets over $10 million. He interfaced with licensing and biz dev groups at 200 pharma companies. He worked with FDA. He invented 5 medical patents.
    He speaks 6 languages.
    His undergrad at Humboldt State Uni. BA in Business and BA in French. Biology studies. Graduate school at Uni. of California, Santa Barbara, statistics, and San Francisco State Uni., MBA.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free